This inventor holds 1 USPTO granted patent. Top assignee: Gwo XI Stem Cell Applied Technology Co., Ltd.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Wei Wu Li: Innovator in Stem Cell Technology
Introduction
Wei Wu Li is a prominent inventor based in Zhubei, Taiwan. He has made significant contributions to the field of stem cell research, particularly in developing innovative methods for treating neurodegenerative diseases. His work focuses on harnessing the potential of mesenchymal stem cells to create effective medical solutions.
Latest Patents
Wei Wu Li holds a patent for "High-expression type mesenchymal stem cells, culture method and use thereof." This invention provides a groundbreaking medicine for treating neurodegenerative diseases. It utilizes LEFTY2, a factor generated by co-culturing mesenchymal stem cells with nerve cells that have mutations in the APP gene. The LEFTY2 plays a crucial role in inhibiting Beta amyloid and hyperphosphorylated Tau protein, which are significant contributors to neurodegenerative conditions. Importantly, this method does not adversely affect the development of nerve cells and promotes their growth.
Career Highlights
Wei Wu Li is associated with Gwo Xi Stem Cell Applied Technology Co., Ltd., where he continues to advance his research and innovations. His work has garnered attention for its potential to revolutionize treatments for conditions such as Alzheimer's disease and other neurodegenerative disorders.
Collaborations
Wei Wu Li collaborates with notable colleagues, including Tzyy-Wen Chiou and Horng-Jyh Harn. Their combined expertise enhances the research and development efforts at Gwo Xi Stem Cell Applied Technology Co., Ltd.
Conclusion
Wei Wu Li's contributions to stem cell technology and neurodegenerative disease treatment highlight his role as an influential inventor in the medical field. His innovative approaches promise to improve the lives of many affected by these challenging conditions.